HLA 同种免疫导致的血小板输注无效：机制和管理方面的不断变化的模式。
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
机构信息
Clinical Research Division, Fred Hutchinson Cancer Center, United States of America; BloodWorks NorthWest, United States of America.
BloodWorks NorthWest, United States of America; Division of Hematology and Oncology, University of Washington School of Medicine, United States of America.
出版信息
Blood Rev. 2023 Nov;62:101135. doi: 10.1016/j.blre.2023.101135. Epub 2023 Oct 2.
Platelet transfusion refractoriness due to HLA alloimmunization presents a significant medical problem, particularly among multiply transfused patients with hematologic malignancies and those undergoing hematopoietic stem cell transplants. HLA compatible platelet transfusions also impose significant financial burden on these patients. Recently, several novel mechanisms have been described in the development of HLA alloimmunization and platelet transfusion refractoriness. We review the history of platelet transfusions and mechanisms of HLA-sensitization and transfusion refractoriness. We also summarize advances in the diagnosis and treatment of platelet transfusion refractoriness due to HLA alloimmunization.
由于 HLA 同种免疫导致的血小板输注无效是一个重大的医学问题，尤其是在接受多次输血的血液系统恶性肿瘤患者和接受造血干细胞移植的患者中。HLA 相容的血小板输注也给这些患者带来了巨大的经济负担。最近，人们描述了 HLA 同种免疫和血小板输注无效发展中的几种新机制。我们回顾了血小板输注的历史以及 HLA 致敏和输血无效的机制。我们还总结了 HLA 同种免疫导致的血小板输注无效的诊断和治疗进展。
Zotero 插件